Sage Therapeutics said on Wednesday it would stop the development of its experimental drug, dalzanemdor, following the latest failure in a study testing it in Huntington's disease. The company's ...
It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback